Trust Investment Advisors cut its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 24.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,525 shares of the biopharmaceutical company’s stock after selling 3,825 shares during the quarter. Trust Investment Advisors’ holdings in Bristol-Myers Squibb were worth $599,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in BMY. Portfolio Solutions LLC bought a new position in Bristol-Myers Squibb in the 4th quarter worth $37,000. Gantzert Investment Co. LLC ADV bought a new position in Bristol-Myers Squibb in the 4th quarter worth $39,000. Arlington Partners LLC raised its holdings in Bristol-Myers Squibb by 40.0% in the 4th quarter. Arlington Partners LLC now owns 1,400 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 400 shares during the period. Financial Gravity Companies Inc. bought a new position in Bristol-Myers Squibb in the 4th quarter worth $90,000. Finally, ETF Managers Group LLC raised its holdings in Bristol-Myers Squibb by 18.7% in the 4th quarter. ETF Managers Group LLC now owns 2,086 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 328 shares during the period. 72.56% of the stock is currently owned by institutional investors and hedge funds.
Shares of BMY stock opened at $51.66 on Friday. Bristol-Myers Squibb Co has a 52-week low of $44.30 and a 52-week high of $68.22. The company has a quick ratio of 1.40, a current ratio of 1.53 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $83.21 billion, a price-to-earnings ratio of 12.98, a price-to-earnings-growth ratio of 2.25 and a beta of 0.83.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.09. Bristol-Myers Squibb had a return on equity of 50.03% and a net margin of 21.95%. The business had revenue of $5.97 billion during the quarter, compared to analyst estimates of $5.95 billion. During the same quarter in the prior year, the business posted $0.68 EPS. Bristol-Myers Squibb’s revenue for the quarter was up 9.6% compared to the same quarter last year. Analysts expect that Bristol-Myers Squibb Co will post 4.15 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Friday, February 1st. Shareholders of record on Friday, January 4th were paid a $0.41 dividend. This represents a $1.64 dividend on an annualized basis and a yield of 3.17%. The ex-dividend date was Thursday, January 3rd. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.40. Bristol-Myers Squibb’s dividend payout ratio is presently 41.21%.
A number of equities analysts recently commented on the company. Credit Suisse Group reaffirmed a “hold” rating and issued a $59.00 target price on shares of Bristol-Myers Squibb in a report on Thursday, December 13th. BMO Capital Markets raised their target price on Bristol-Myers Squibb from $55.00 to $58.00 and gave the stock a “market perform” rating in a report on Friday, November 16th. ValuEngine raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Friday, December 7th. William Blair reaffirmed an “outperform” rating on shares of Bristol-Myers Squibb in a report on Tuesday, November 27th. Finally, Societe Generale set a $47.00 target price on Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Wednesday, November 14th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and seven have issued a buy rating to the company’s stock. Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus target price of $60.03.
COPYRIGHT VIOLATION NOTICE: “Trust Investment Advisors Has $599,000 Position in Bristol-Myers Squibb Co (BMY)” was reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://transcriptdaily.com/2019/03/01/trust-investment-advisors-has-599000-position-in-bristol-myers-squibb-co-bmy-2.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an inhibitor targeted at stroke prevention in atrial fibrillation and prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Read More: What is the 52-week high/low?
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.